All

1003 Expert Conversations

    1003 Expert Conversations
    Esophageal cancer treatment FAQ. Prognosis. When surgery is not beneficial? 11
    ¥0
    Future in esophageal cancer treatment. Precision medicine. Tumor genome sequencing. 10
    ¥0
    Lung cancer treatment. Minimally invasive surgery. VATS. Robotic surgery for lung cancer. 9
    ¥0
    Esophageal carcinoma. Minimally invasive surgery vs. classic surgery. Surgeon’s skill is paramount. 8
    ¥0
    Esophageal carcinoma radiotherapy. ‘East’ vs. ‘West’ differences in radiotherapy use. 7
    ¥0
    Esophageal carcinoma. Neoadjuvant chemotherapy vs. upfront surgery. 6
    ¥0
    Esophageal carcinoma diagnosis. PET CT. Endoscopic ultrasound. Cure at early stage is possible. 5
    ¥0
    Esophageal carcinoma risks and symptoms. ‘East’ vs. ‘West’ differences in esophageal cancer. 4
    ¥0
    GERD anti-reflux surgery often fails after 10 years. PPI medications and esophageal cancer risk. 3
    ¥0
    Does GERD anti-reflux surgery reduce esophageal cancer risks? The risk does not go down to zero. 2
    ¥0
    Dr. Jari Rasanen. Esophageal cancer and Lung cancer expert. Biography. 0
    ¥0
    How to select drug combinations for multiple myeloma treatment? 7
    ¥0
    Multiple myeloma. Message of hope for cancer treatment and for life. 14
    ¥0
    Multiple myeloma. Patient’s story: elderly woman and ‘last hope’ CAR T-cell therapy. 13
    ¥0
    Multiple myeloma. FAQ: Immunization, Vitamin D and bone health, quality of life. 12
    ¥0
    Future in multiple myeloma treatment. When will it be a ‘curable disease’? 11
    ¥0
    Castleman Disease. Subtypes and treatment options. 10
    ¥0
    Multiple myeloma. Minimal Residual Disease evaluation. Prognosis. 9
    ¥0
    Chimeric antigen receptor T-cell therapy in multiple myeloma. CAR T-cell immunotherapy. 8
    ¥0
    Autologous stem cell transplantation in multiple myeloma. 6
    ¥0
    Multiple myeloma. Risk stratification criteria to select the best treatment for each patient. 5
    ¥0
    Multiple myeloma and gene expression profiling. Intraclonal heterogeneity. 4
    ¥0
    Multiple myeloma and bone marrow microenvironment. ‘Seed and soil’ concept in cancer progression. 3
    ¥0
    Multiple myeloma. Genetic changes. MGUS. Smoldering myeloma. 2
    ¥0
    Multiple myeloma. Progress and challenges of treatment. 1
    ¥0
    Dr. Nikhil Munshi. Multiple myeloma expert. Biography. 0
    ¥0
    ‘Mentorship is crucial for successful medical career’. Prof. Scott L. Friedman. 18
    ¥0
    Most patients with fatty liver disease & NASH do not have symptoms. Alcohol is often not to blame. 17
    ¥0
    How to improve health of your liver? Difficulty to keep low weight. 16
    ¥0
    FAQ from patients with fatty liver disease. Life quality, prognosis, alcohol use. 15
    ¥0
    Future of liver disease treatment. Xenotransplantation of liver. 14
    ¥0
    Coffee reduces risks of liver disease. Coffee and NAFLD prevention. 13
    ¥0
    Leading drug candidates for NASH therapy. NAFLD, fatty liver disease treatment. 12
    ¥0
    When new drugs will be approved for fatty liver disease? 11
    ¥0
    Liver cancer risk and fatty liver disease. Cancer screening in NASH, NAFLD. 10
    ¥0
    Hepatic Stellate Cells cause fatty liver disease. NAFLD and NASH causes. 9
    ¥0
    Food supplements and generic drugs for NASH and NAFLD. 8
    ¥0
    Gut microbiome and fatty liver disease. NAFLD, NASH, and Fecal transplantation. 7
    ¥0
    Genetic tests to find risks for liver disease [NAFLD and NASH]. 6
    ¥0
    How NASH differs from NAFLD. What drives progression to NASH? 5
    ¥0
    Recently viewed Expert Conversations